Copyright Reports & Markets. All rights reserved.

Global Hit-to-Lead (H2L) in Drug Discovery Market 2024 by Company, Regions, Type and Application, Forecast to 2030

Request for Sample of this report
Buy now

1 Market Overview

  • 1.1 Product Overview and Scope
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Classification of Hit-to-Lead (H2L) in Drug Discovery by Type
    • 1.3.1 Overview: Global Hit-to-Lead (H2L) in Drug Discovery Market Size by Type: 2019 Versus 2023 Versus 2030
    • 1.3.2 Global Hit-to-Lead (H2L) in Drug Discovery Consumption Value Market Share by Type in 2023
    • 1.3.3 Small Molecules
    • 1.3.4 Biologics
  • 1.4 Global Hit-to-Lead (H2L) in Drug Discovery Market by Application
    • 1.4.1 Overview: Global Hit-to-Lead (H2L) in Drug Discovery Market Size by Application: 2019 Versus 2023 Versus 2030
    • 1.4.2 Biopharmaceutical Companies
    • 1.4.3 Government and Academic Institutes
    • 1.4.4 Others
  • 1.5 Global Hit-to-Lead (H2L) in Drug Discovery Market Size & Forecast
  • 1.6 Global Hit-to-Lead (H2L) in Drug Discovery Market Size and Forecast by Region
    • 1.6.1 Global Hit-to-Lead (H2L) in Drug Discovery Market Size by Region: 2019 VS 2023 VS 2030
    • 1.6.2 Global Hit-to-Lead (H2L) in Drug Discovery Market Size by Region, (2019-2030)
    • 1.6.3 North America Hit-to-Lead (H2L) in Drug Discovery Market Size and Prospect (2019-2030)
    • 1.6.4 Europe Hit-to-Lead (H2L) in Drug Discovery Market Size and Prospect (2019-2030)
    • 1.6.5 Asia-Pacific Hit-to-Lead (H2L) in Drug Discovery Market Size and Prospect (2019-2030)
    • 1.6.6 South America Hit-to-Lead (H2L) in Drug Discovery Market Size and Prospect (2019-2030)
    • 1.6.7 Middle East & Africa Hit-to-Lead (H2L) in Drug Discovery Market Size and Prospect (2019-2030)

2 Company Profiles

  • 2.1 Oncodesign Services
    • 2.1.1 Oncodesign Services Details
    • 2.1.2 Oncodesign Services Major Business
    • 2.1.3 Oncodesign Services Hit-to-Lead (H2L) in Drug Discovery Product and Solutions
    • 2.1.4 Oncodesign Services Hit-to-Lead (H2L) in Drug Discovery Revenue, Gross Margin and Market Share (2019-2024)
    • 2.1.5 Oncodesign Services Recent Developments and Future Plans
  • 2.2 Enzymlogic
    • 2.2.1 Enzymlogic Details
    • 2.2.2 Enzymlogic Major Business
    • 2.2.3 Enzymlogic Hit-to-Lead (H2L) in Drug Discovery Product and Solutions
    • 2.2.4 Enzymlogic Hit-to-Lead (H2L) in Drug Discovery Revenue, Gross Margin and Market Share (2019-2024)
    • 2.2.5 Enzymlogic Recent Developments and Future Plans
  • 2.3 Dalriada
    • 2.3.1 Dalriada Details
    • 2.3.2 Dalriada Major Business
    • 2.3.3 Dalriada Hit-to-Lead (H2L) in Drug Discovery Product and Solutions
    • 2.3.4 Dalriada Hit-to-Lead (H2L) in Drug Discovery Revenue, Gross Margin and Market Share (2019-2024)
    • 2.3.5 Dalriada Recent Developments and Future Plans
  • 2.4 Immunocure
    • 2.4.1 Immunocure Details
    • 2.4.2 Immunocure Major Business
    • 2.4.3 Immunocure Hit-to-Lead (H2L) in Drug Discovery Product and Solutions
    • 2.4.4 Immunocure Hit-to-Lead (H2L) in Drug Discovery Revenue, Gross Margin and Market Share (2019-2024)
    • 2.4.5 Immunocure Recent Developments and Future Plans
  • 2.5 Jubilant Biosys
    • 2.5.1 Jubilant Biosys Details
    • 2.5.2 Jubilant Biosys Major Business
    • 2.5.3 Jubilant Biosys Hit-to-Lead (H2L) in Drug Discovery Product and Solutions
    • 2.5.4 Jubilant Biosys Hit-to-Lead (H2L) in Drug Discovery Revenue, Gross Margin and Market Share (2019-2024)
    • 2.5.5 Jubilant Biosys Recent Developments and Future Plans
  • 2.6 Wuxi AppTec
    • 2.6.1 Wuxi AppTec Details
    • 2.6.2 Wuxi AppTec Major Business
    • 2.6.3 Wuxi AppTec Hit-to-Lead (H2L) in Drug Discovery Product and Solutions
    • 2.6.4 Wuxi AppTec Hit-to-Lead (H2L) in Drug Discovery Revenue, Gross Margin and Market Share (2019-2024)
    • 2.6.5 Wuxi AppTec Recent Developments and Future Plans
  • 2.7 Domainex
    • 2.7.1 Domainex Details
    • 2.7.2 Domainex Major Business
    • 2.7.3 Domainex Hit-to-Lead (H2L) in Drug Discovery Product and Solutions
    • 2.7.4 Domainex Hit-to-Lead (H2L) in Drug Discovery Revenue, Gross Margin and Market Share (2019-2024)
    • 2.7.5 Domainex Recent Developments and Future Plans
  • 2.8 Evotec
    • 2.8.1 Evotec Details
    • 2.8.2 Evotec Major Business
    • 2.8.3 Evotec Hit-to-Lead (H2L) in Drug Discovery Product and Solutions
    • 2.8.4 Evotec Hit-to-Lead (H2L) in Drug Discovery Revenue, Gross Margin and Market Share (2019-2024)
    • 2.8.5 Evotec Recent Developments and Future Plans
  • 2.9 NorthEast BioLab
    • 2.9.1 NorthEast BioLab Details
    • 2.9.2 NorthEast BioLab Major Business
    • 2.9.3 NorthEast BioLab Hit-to-Lead (H2L) in Drug Discovery Product and Solutions
    • 2.9.4 NorthEast BioLab Hit-to-Lead (H2L) in Drug Discovery Revenue, Gross Margin and Market Share (2019-2024)
    • 2.9.5 NorthEast BioLab Recent Developments and Future Plans
  • 2.10 SciLifeLab
    • 2.10.1 SciLifeLab Details
    • 2.10.2 SciLifeLab Major Business
    • 2.10.3 SciLifeLab Hit-to-Lead (H2L) in Drug Discovery Product and Solutions
    • 2.10.4 SciLifeLab Hit-to-Lead (H2L) in Drug Discovery Revenue, Gross Margin and Market Share (2019-2024)
    • 2.10.5 SciLifeLab Recent Developments and Future Plans
  • 2.11 Honarnejad
    • 2.11.1 Honarnejad Details
    • 2.11.2 Honarnejad Major Business
    • 2.11.3 Honarnejad Hit-to-Lead (H2L) in Drug Discovery Product and Solutions
    • 2.11.4 Honarnejad Hit-to-Lead (H2L) in Drug Discovery Revenue, Gross Margin and Market Share (2019-2024)
    • 2.11.5 Honarnejad Recent Developments and Future Plans
  • 2.12 Sygnature Discovery
    • 2.12.1 Sygnature Discovery Details
    • 2.12.2 Sygnature Discovery Major Business
    • 2.12.3 Sygnature Discovery Hit-to-Lead (H2L) in Drug Discovery Product and Solutions
    • 2.12.4 Sygnature Discovery Hit-to-Lead (H2L) in Drug Discovery Revenue, Gross Margin and Market Share (2019-2024)
    • 2.12.5 Sygnature Discovery Recent Developments and Future Plans
  • 2.13 Creative Biolabs
    • 2.13.1 Creative Biolabs Details
    • 2.13.2 Creative Biolabs Major Business
    • 2.13.3 Creative Biolabs Hit-to-Lead (H2L) in Drug Discovery Product and Solutions
    • 2.13.4 Creative Biolabs Hit-to-Lead (H2L) in Drug Discovery Revenue, Gross Margin and Market Share (2019-2024)
    • 2.13.5 Creative Biolabs Recent Developments and Future Plans
  • 2.14 Bioduro-Sundia
    • 2.14.1 Bioduro-Sundia Details
    • 2.14.2 Bioduro-Sundia Major Business
    • 2.14.3 Bioduro-Sundia Hit-to-Lead (H2L) in Drug Discovery Product and Solutions
    • 2.14.4 Bioduro-Sundia Hit-to-Lead (H2L) in Drug Discovery Revenue, Gross Margin and Market Share (2019-2024)
    • 2.14.5 Bioduro-Sundia Recent Developments and Future Plans

3 Market Competition, by Players

  • 3.1 Global Hit-to-Lead (H2L) in Drug Discovery Revenue and Share by Players (2019-2024)
  • 3.2 Market Share Analysis (2023)
    • 3.2.1 Market Share of Hit-to-Lead (H2L) in Drug Discovery by Company Revenue
    • 3.2.2 Top 3 Hit-to-Lead (H2L) in Drug Discovery Players Market Share in 2023
    • 3.2.3 Top 6 Hit-to-Lead (H2L) in Drug Discovery Players Market Share in 2023
  • 3.3 Hit-to-Lead (H2L) in Drug Discovery Market: Overall Company Footprint Analysis
    • 3.3.1 Hit-to-Lead (H2L) in Drug Discovery Market: Region Footprint
    • 3.3.2 Hit-to-Lead (H2L) in Drug Discovery Market: Company Product Type Footprint
    • 3.3.3 Hit-to-Lead (H2L) in Drug Discovery Market: Company Product Application Footprint
  • 3.4 New Market Entrants and Barriers to Market Entry
  • 3.5 Mergers, Acquisition, Agreements, and Collaborations

4 Market Size Segment by Type

  • 4.1 Global Hit-to-Lead (H2L) in Drug Discovery Consumption Value and Market Share by Type (2019-2024)
  • 4.2 Global Hit-to-Lead (H2L) in Drug Discovery Market Forecast by Type (2025-2030)

5 Market Size Segment by Application

  • 5.1 Global Hit-to-Lead (H2L) in Drug Discovery Consumption Value Market Share by Application (2019-2024)
  • 5.2 Global Hit-to-Lead (H2L) in Drug Discovery Market Forecast by Application (2025-2030)

6 North America

  • 6.1 North America Hit-to-Lead (H2L) in Drug Discovery Consumption Value by Type (2019-2030)
  • 6.2 North America Hit-to-Lead (H2L) in Drug Discovery Market Size by Application (2019-2030)
  • 6.3 North America Hit-to-Lead (H2L) in Drug Discovery Market Size by Country
    • 6.3.1 North America Hit-to-Lead (H2L) in Drug Discovery Consumption Value by Country (2019-2030)
    • 6.3.2 United States Hit-to-Lead (H2L) in Drug Discovery Market Size and Forecast (2019-2030)
    • 6.3.3 Canada Hit-to-Lead (H2L) in Drug Discovery Market Size and Forecast (2019-2030)
    • 6.3.4 Mexico Hit-to-Lead (H2L) in Drug Discovery Market Size and Forecast (2019-2030)

7 Europe

  • 7.1 Europe Hit-to-Lead (H2L) in Drug Discovery Consumption Value by Type (2019-2030)
  • 7.2 Europe Hit-to-Lead (H2L) in Drug Discovery Consumption Value by Application (2019-2030)
  • 7.3 Europe Hit-to-Lead (H2L) in Drug Discovery Market Size by Country
    • 7.3.1 Europe Hit-to-Lead (H2L) in Drug Discovery Consumption Value by Country (2019-2030)
    • 7.3.2 Germany Hit-to-Lead (H2L) in Drug Discovery Market Size and Forecast (2019-2030)
    • 7.3.3 France Hit-to-Lead (H2L) in Drug Discovery Market Size and Forecast (2019-2030)
    • 7.3.4 United Kingdom Hit-to-Lead (H2L) in Drug Discovery Market Size and Forecast (2019-2030)
    • 7.3.5 Russia Hit-to-Lead (H2L) in Drug Discovery Market Size and Forecast (2019-2030)
    • 7.3.6 Italy Hit-to-Lead (H2L) in Drug Discovery Market Size and Forecast (2019-2030)

8 Asia-Pacific

  • 8.1 Asia-Pacific Hit-to-Lead (H2L) in Drug Discovery Consumption Value by Type (2019-2030)
  • 8.2 Asia-Pacific Hit-to-Lead (H2L) in Drug Discovery Consumption Value by Application (2019-2030)
  • 8.3 Asia-Pacific Hit-to-Lead (H2L) in Drug Discovery Market Size by Region
    • 8.3.1 Asia-Pacific Hit-to-Lead (H2L) in Drug Discovery Consumption Value by Region (2019-2030)
    • 8.3.2 China Hit-to-Lead (H2L) in Drug Discovery Market Size and Forecast (2019-2030)
    • 8.3.3 Japan Hit-to-Lead (H2L) in Drug Discovery Market Size and Forecast (2019-2030)
    • 8.3.4 South Korea Hit-to-Lead (H2L) in Drug Discovery Market Size and Forecast (2019-2030)
    • 8.3.5 India Hit-to-Lead (H2L) in Drug Discovery Market Size and Forecast (2019-2030)
    • 8.3.6 Southeast Asia Hit-to-Lead (H2L) in Drug Discovery Market Size and Forecast (2019-2030)
    • 8.3.7 Australia Hit-to-Lead (H2L) in Drug Discovery Market Size and Forecast (2019-2030)

9 South America

  • 9.1 South America Hit-to-Lead (H2L) in Drug Discovery Consumption Value by Type (2019-2030)
  • 9.2 South America Hit-to-Lead (H2L) in Drug Discovery Consumption Value by Application (2019-2030)
  • 9.3 South America Hit-to-Lead (H2L) in Drug Discovery Market Size by Country
    • 9.3.1 South America Hit-to-Lead (H2L) in Drug Discovery Consumption Value by Country (2019-2030)
    • 9.3.2 Brazil Hit-to-Lead (H2L) in Drug Discovery Market Size and Forecast (2019-2030)
    • 9.3.3 Argentina Hit-to-Lead (H2L) in Drug Discovery Market Size and Forecast (2019-2030)

10 Middle East & Africa

  • 10.1 Middle East & Africa Hit-to-Lead (H2L) in Drug Discovery Consumption Value by Type (2019-2030)
  • 10.2 Middle East & Africa Hit-to-Lead (H2L) in Drug Discovery Consumption Value by Application (2019-2030)
  • 10.3 Middle East & Africa Hit-to-Lead (H2L) in Drug Discovery Market Size by Country
    • 10.3.1 Middle East & Africa Hit-to-Lead (H2L) in Drug Discovery Consumption Value by Country (2019-2030)
    • 10.3.2 Turkey Hit-to-Lead (H2L) in Drug Discovery Market Size and Forecast (2019-2030)
    • 10.3.3 Saudi Arabia Hit-to-Lead (H2L) in Drug Discovery Market Size and Forecast (2019-2030)
    • 10.3.4 UAE Hit-to-Lead (H2L) in Drug Discovery Market Size and Forecast (2019-2030)

11 Market Dynamics

  • 11.1 Hit-to-Lead (H2L) in Drug Discovery Market Drivers
  • 11.2 Hit-to-Lead (H2L) in Drug Discovery Market Restraints
  • 11.3 Hit-to-Lead (H2L) in Drug Discovery Trends Analysis
  • 11.4 Porters Five Forces Analysis
    • 11.4.1 Threat of New Entrants
    • 11.4.2 Bargaining Power of Suppliers
    • 11.4.3 Bargaining Power of Buyers
    • 11.4.4 Threat of Substitutes
    • 11.4.5 Competitive Rivalry

12 Industry Chain Analysis

  • 12.1 Hit-to-Lead (H2L) in Drug Discovery Industry Chain
  • 12.2 Hit-to-Lead (H2L) in Drug Discovery Upstream Analysis
  • 12.3 Hit-to-Lead (H2L) in Drug Discovery Midstream Analysis
  • 12.4 Hit-to-Lead (H2L) in Drug Discovery Downstream Analysis

13 Research Findings and Conclusion

    14 Appendix

    • 14.1 Methodology
    • 14.2 Research Process and Data Source

    In drug discovery, Hit-to-Lead (H2L) is a critical phase that follows the identification of initial "hits" from high-throughput screening or other lead generation methods. The goal of the H2L stage is to optimize these hit compounds to become more promising lead candidates for further development.
    According to our (Global Info Research) latest study, the global Hit-to-Lead (H2L) in Drug Discovery market size was valued at US$ million in 2023 and is forecast to a readjusted size of USD million by 2030 with a CAGR of %during review period.
    This report is a detailed and comprehensive analysis for global Hit-to-Lead (H2L) in Drug Discovery market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2024, are provided.
    Key Features:
    Global Hit-to-Lead (H2L) in Drug Discovery market size and forecasts, in consumption value ($ Million), 2019-2030
    Global Hit-to-Lead (H2L) in Drug Discovery market size and forecasts by region and country, in consumption value ($ Million), 2019-2030
    Global Hit-to-Lead (H2L) in Drug Discovery market size and forecasts, by Type and by Application, in consumption value ($ Million), 2019-2030
    Global Hit-to-Lead (H2L) in Drug Discovery market shares of main players, in revenue ($ Million), 2019-2024
    The Primary Objectives in This Report Are:
    To determine the size of the total market opportunity of global and key countries
    To assess the growth potential for Hit-to-Lead (H2L) in Drug Discovery
    To forecast future growth in each product and end-use market
    To assess competitive factors affecting the marketplace
    This report profiles key players in the global Hit-to-Lead (H2L) in Drug Discovery market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Oncodesign Services, Enzymlogic, Dalriada, Immunocure, Jubilant Biosys, Wuxi AppTec, Domainex, Evotec, NorthEast BioLab, SciLifeLab, etc.
    This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
    Market segmentation
    Hit-to-Lead (H2L) in Drug Discovery market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
    Market segmentation
    Hit-to-Lead (H2L) in Drug Discovery market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
    Market segment by Type
    Small Molecules
    Biologics
    Market segment by Application
    Biopharmaceutical Companies
    Government and Academic Institutes
    Others
    Market segment by players, this report covers
    Oncodesign Services
    Enzymlogic
    Dalriada
    Immunocure
    Jubilant Biosys
    Wuxi AppTec
    Domainex
    Evotec
    NorthEast BioLab
    SciLifeLab
    Honarnejad
    Sygnature Discovery
    Creative Biolabs
    Bioduro-Sundia
    Market segment by regions, regional analysis covers
    North America (United States, Canada and Mexico)
    Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
    Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
    South America (Brazil, Rest of South America)
    Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
    The content of the study subjects, includes a total of 13 chapters:
    Chapter 1, to describe Hit-to-Lead (H2L) in Drug Discovery product scope, market overview, market estimation caveats and base year.
    Chapter 2, to profile the top players of Hit-to-Lead (H2L) in Drug Discovery, with revenue, gross margin, and global market share of Hit-to-Lead (H2L) in Drug Discovery from 2019 to 2024.
    Chapter 3, the Hit-to-Lead (H2L) in Drug Discovery competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
    Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2019 to 2030.
    Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2019 to 2024.and Hit-to-Lead (H2L) in Drug Discovery market forecast, by regions, by Type and by Application, with consumption value, from 2024 to 2030.
    Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
    Chapter 12, the key raw materials and key suppliers, and industry chain of Hit-to-Lead (H2L) in Drug Discovery.
    Chapter 13, to describe Hit-to-Lead (H2L) in Drug Discovery research findings and conclusion.

    Buy now